DRNA Key Statistics, Chart & Performance
The current stock price of DRNA is 38.22 null. In the past month the price increased by 0.61%. In the past year, price increased by 73.49%.
DRNA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to DRNA. When comparing the yearly performance of all stocks, DRNA is one of the better performing stocks in the market, outperforming 98.23% of all stocks.
DRNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DRNA. Both the profitability and the financial health of DRNA get a neutral evaluation. Nothing too spectacular is happening here.
DRNA Financial Highlights
Over the last trailing twelve months DRNA reported a non-GAAP Earnings per Share(EPS) of -1.63. The EPS decreased by -1.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -64.53% | ||
| ROA | -16.12% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
DRNA Forecast & Estimates
14 analysts have analysed DRNA and the average price target is 37.16 null. This implies a price decrease of -2.78% is expected in the next year compared to the current price of 38.22.
For the next year, analysts expect an EPS growth of -13.03% and a revenue growth -6.12% for DRNA
DRNA Ownership
DRNA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.49 | 394.585B | ||
| AMGN | AMGEN INC | 16.37 | 202.372B | ||
| GILD | GILEAD SCIENCES INC | 16.76 | 188.186B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.91 | 119.469B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.45 | 82.007B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.83 | 42.275B | ||
| INSM | INSMED INC | N/A | 31.892B | ||
| NTRA | NATERA INC | N/A | 29.062B | ||
| BIIB | BIOGEN INC | 12.6 | 28.432B | ||
| INCY | INCYTE CORP | 12.65 | 21.405B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DRNA
Company Profile
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The company is headquartered in Lexington, Massachusetts and currently employs 302 full-time employees. The company went IPO on 2014-01-30. The firm is focused on discovering, developing, and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. The firm's GalXC RNAi technology Platform consists of its liver-targeted GalXC technology and GalXC-Plus technology for tissues outside the liver. The firm's product line includes nedosiran, RG6346, belcesiran, and DCR-AUD. Its lead product candiadate nedosiran is a RNAi drug candidate developed for the treatment of hyperoxaluria (PH). The RG6346 for the treatment of chronic hepatitis B virus (HBV) infection. The belcesiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease (AATLD). The DCR-AUD for the treatment of alcohol use disorder (AUD).
Company Info
Dicerna Pharmaceuticals Inc
75 Hayden Avenue
Lexington MASSACHUSETTS 02421 US
CEO: Douglas M. Fambrough
Employees: 302
Phone: 16176218097.0
Dicerna Pharmaceuticals Inc / DRNA FAQ
What does DRNA do?
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The company is headquartered in Lexington, Massachusetts and currently employs 302 full-time employees. The company went IPO on 2014-01-30. The firm is focused on discovering, developing, and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. The firm's GalXC RNAi technology Platform consists of its liver-targeted GalXC technology and GalXC-Plus technology for tissues outside the liver. The firm's product line includes nedosiran, RG6346, belcesiran, and DCR-AUD. Its lead product candiadate nedosiran is a RNAi drug candidate developed for the treatment of hyperoxaluria (PH). The RG6346 for the treatment of chronic hepatitis B virus (HBV) infection. The belcesiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease (AATLD). The DCR-AUD for the treatment of alcohol use disorder (AUD).
Can you provide the latest stock price for Dicerna Pharmaceuticals Inc?
The current stock price of DRNA is 38.22 null. The price increased by 0.58% in the last trading session.
Does Dicerna Pharmaceuticals Inc pay dividends?
DRNA does not pay a dividend.
How is the ChartMill rating for Dicerna Pharmaceuticals Inc?
DRNA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for DRNA stock?
14 analysts have analysed DRNA and the average price target is 37.16 null. This implies a price decrease of -2.78% is expected in the next year compared to the current price of 38.22.
Can you provide the market cap for Dicerna Pharmaceuticals Inc?
Dicerna Pharmaceuticals Inc (DRNA) has a market capitalization of 2.97B null. This makes DRNA a Mid Cap stock.
When does Dicerna Pharmaceuticals Inc (DRNA) report earnings?
Dicerna Pharmaceuticals Inc (DRNA) will report earnings on 2022-03-04, after the market close.